However, biologic therapies targeting key inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interleukin-23 (IL-23) have significantly advanced the management of moderate to severe psoriasis​ [4,5]. This evidence concerns the gene IL37 and psoriasis.